Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07289880
Recruiting Not applicable

Efficacy of Diacylglycerol Oil on Metabolic Risk Factors in Prediabetes

NCT07289880 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital of Guangdong Pharmaceutical University
Phase
Not applicable
Started
2025-12-30
Last updated
2026-10-21

Condition(s) studied

Prediabetes

Investigational drug(s) / intervention(s)

Diacylglycerol oilColza Oil

Diacylglycerol oil: This study will implement a four-week dietary intervention in which participants assigned to the intervention group will replace their habitual cooking oil with diacylglycerol (DAG) oil. All other lifestyle behaviors will be maintained without modification.

Colza Oil: Participants assigned to the control group will consume colza oil as their cooking oil throughout a four-week dietary intervention. No other lifestyle habits or dietary behaviors will be altered.

Study summary

This study will implement a four-week dietary intervention among middle-aged and older adults with pre-diabetes. Participants assigned to the intervention arm will replace their usual cooking oil with diacylglycerol (DAG) oil, while those in the control arm will consume colza oil. All other lifestyle behaviors will be maintained without modification. The trial will determine the impact of DAG oil consumption on glycemic regulation, lipid metabolism, and body composition in this high-risk population.

Eligibility

Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Aged 40-75 years. 2. Diagnosed with prediabetes according to American Diabetes Association (ADA) criteria: including fasting plasma glucose (FPG) levels of 5.6-6.9 mmol/L, and/or 2-hour postprandial glucose (OGTT-2h) levels of 7.8-11.1 mmol/L, and/or glycated hemoglobin (HbA1c) levels of 5.7%-6.4%. 3. Body mass index (BMI) ≥ 24 kg/m². 4. No plans to relocate or travel extensively in the next three months. 5. Willing to consume all study-provided meals throughout the intervention. 6. Willing and able to provide written informed consent. Exclusion Criteria: 1. Diagnosis of diabetes (Type 1 or Type 2). 2. Current use of any glucose-lowering medication. 3. Use of appetite suppressants or hormonal medications. 4. History of bariatric surgery, or weight change \>5% in the past 3 months. 5. Alcohol consumption \>40 g/day. 6. Use of antibiotics, probiotics, or prebiotics within the past 3 months. 7. Pregnancy, lactation or planning pregnancy. 8. History of severe cardiovascular disease, malignancy, autoimmune disease, cognitive impairment, or severe dysfunction of thyroid, liver, kidney, or digestive system. 9. Inability to comprehend information, communicate effectively, or comply with the study protocol.

Primary outcome measure(s)

  • Continuous Glucose Monitoring (CGM) Data — up to 4 weeks
    At baseline, and 4 weeks, investigators will using Continuous Glucose Monitoring (CGM) to monitor the glucose level of participants.

Trial sites (1)

FacilityCityRegionStatus
Beijing Street Guangzhou Guangdong Recruiting

Other trials for the same condition

Multicenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency Ultrasound Starting soon
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) Starting soon
Effect of Metformin on Healthy Live Birth in Women With Prediabetes Recruiting
Different Aerobic-to-Resistance Training Ratios in Adults Aged 50 Years and Older With Prediabetes Starting soon
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07289880 on ClinicalTrials.gov ↗ ← All trials in China